Ixhalanex

Alprazolam, the active ingredient in Ixhalanex, is a benzodiazepine presented as an oral tablet for oral use. It treats generalized anxiety disorder and panic disorder in adults.

GNH USA supplies Ixhalanex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ixhalanex (alprazolam) acts on the central nervous system to alleviate anxiety‑related conditions.

- Generalized anxiety disorder: reduces excessive worry and tension. - Panic disorder: decreases the frequency and severity of panic attacks. - Anxiety associated with depression: provides short‑term relief of anxiety symptoms in depressive states.

Adverse reactions may occur with alprazolam use and vary in frequency and severity.

Common Side Effects: - Drowsiness - Fatigue - Dizziness - Impaired coordination - Memory impairment - Blurred vision

Serious or Rare Side Effects: - Respiratory depression - Severe allergic reaction (anaphylaxis) - Mood changes including depression or suicidal thoughts - Dependence and withdrawal syndrome - Paradoxical agitation or aggression - Hepatic dysfunction

Before prescribing alprazolam, clinicians should consider several safety factors. - Pregnancy: Category D – avoid unless benefits outweigh risks. - Elderly: Increased sensitivity – start at the lowest effective dose. - History of substance abuse: heightened risk of dependence. - Concurrent CNS depressants: may amplify sedation and respiratory effects. - Operating machinery: may impair alertness and reaction time. - Store at ambient temperature below 25°C: keep in the original container, protect from moisture.

Alprazolam can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Opioids: additive respiratory depression and profound sedation. - Barbiturates: increased risk of coma and severe CNS depression. - Alcohol: synergistic CNS depressant effects leading to dangerous sedation. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): markedly raise alprazolam plasma levels.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., carbamazepine, phenytoin): may reduce therapeutic effect. - Antidepressants (e.g., SSRIs, SNRIs): monitor for enhanced sedation. - Antihistamines: may increase drowsiness, requiring dose adjustment.